Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers potent efficacy, while its selectivity provides a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch-tracking series examines how the perception and performance of Ocrevus evolves through year 1 in an MS market still waiting for a DMT that balances efficacy and risk better than Tysabri or Tecfidera and in a field that perennially debates the merits of early, aggressive intervention.

What you will learn in this content:

  • What are U.S. neurologists’ awareness of and familiarity with Ocrevus, and what are their perceptions of this product?
  • For which patients are neurologists prescribing Ocrevus, what are their reasons for prescribing in relapsing MS, and how satisfied are they with Ocrevus?
  • What are the promotional messages and activities that Genentech and Roche are employing in support of the Ocrevus launch in relapsing MS?
  • How does the trial and adoption of Ocrevus compare with other recent product launches in the relapsing MS market? How do adopters and nonadopters of Ocrevus in the largest MS subpopulation compare across key metrics?

Product description:

Launch Tracking: Ocrevus (US) Relapsing Forms of Multiple Sclerosisis a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Ocrevus Relapsing Forms of Multiple Sclerosis - Wave 2 (US)
    • Key Findings
    • Benchmarking Ocrevus Launch Success vs. the Competition
      • Six Months Postlaunch, Ocrevus Outperforms Most Benchmark DMTs on Measures of Physician Receptivity and Uptake
    • Prescriber and Nonprescriber Profiles
      • Differences Between Ocrevus Prescribers and Nonprescribers for Relapsing Forms of MS
    • Ocrevus Awareness and Perceptions
      • Unaided and Aided Awareness of Ocrevus
        • Unaided Awareness of Ocrevus Remains High, but Aided Awareness of Certain Clinical Attributes Appears Lower at Six Months Postlaunch
      • Familiarity with Ocrevus
        • Neurologists' Familiarity with Ocrevus Remains High at Six Months Postlaunch
      • Sources of Familiarity with Ocrevus
        • Sources of Familiarity for Ocrevus Are More Marketing-Based at Six Months Postlaunch
      • Initial Reaction to and Interest in Ocrevus
        • Reaction to and Interest in Ocrevus Remains High at Six Months Postlaunch
      • Impressions of Ocrevus
      • Prescriber and Nonprescriber Profiles
        • Wave 2 Ocrevus Prescribers Continue to Show a Tendency Toward More-Aggressive Treatment of MS than Nonprescribers
    • Ocrevus Trial and Use
      • Willingness to Prescribe Ocrevus
        • Surveyed Neurologists' Willingness to Prescribe Ocrevus Remains High at Six Months Postlaunch
      • Number of Patients Currently Receiving Ocrevus
        • Six Months Postlaunch, Robust Uptake of Ocrevus for Relapsing Forms of MS Continues, Mostly in Switch Situations
      • Reasons for Not Yet Prescribing Ocrevus
        • Ocrevus Nonprescribers at Six Months Postlaunch Cite Safety, High Patient Copays, and Familiarity as Barriers to Use
      • Anticipated Ocrevus Use
        • At Six Months Postlaunch, Neurologists Continue to Expect Strong Uptake of Ocrevus in Relapsing Forms of MS
      • Ocrevus Performance on Key Attributes
        • Surveyed Neurologists Continue to Voice High Satisfaction with Ocrevus and Perceive a Safety Advantage over Zinbryta and Lemtrada
    • Effectiveness of Face-to-Face Detailing for Ocrevus
      • Ocrevus Sales Representative Frequency and Reach
        • More Physicians Report Ocrevus Sales Representative Contact at Six Months Postlaunch
      • Satisfaction with Ocrevus Sales Representative
        • Surveyed Neurologists Report High Satisfaction with Ocrevus Sales Representatives at Six Months Postlaunch
      • Ocrevus Message Recall
        • Ocrevus Message Recall at Six Months Postlaunch Centered on Approval for Relapsing Forms of MS and PP-MS
    • Methodology
      • Primary Market Research Methodology
    • Appendix

Author(s): Natalie Taylor, PhD; Jonathan Searles; Sarah Soucy

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Jonathan ;Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, ;Searles received a degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

Sarah Soucy, is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis. Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her in Animal Science with a Bioscience and Technology option and her in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism


Related Reports

Multiple Sclerosis | Access and Reimbursement | US | 2017`

The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (D...

View Details

Multiple Sclerosis | Access & Reimbursement | Detailed, Expanded Analysis (US)

The shifting multiple sclerosis (MS) therapy market continues to evolve as new disease-modifying therapies (DMT

View Details

Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will...

View Details

Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2018

With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the trea...

View Details